\-\ Texto\\:\\ \ \(0\)\
\-\ aphasia\\ and\\ dysarthria\ \(0\)\
\-\ radiation\\ therapy\\ as\\ these\\ tumors\\ are\\ typically\\ very\\ sensitive\\ to\\ radiation\\ therapy\\.\ \(0\)\
\-\ enhancing\\ mass\\ involving\\ left\\ orbit\\,\\ middle\\ cranial\\ fossa\\,\\ maxillary\\ sinus\\,\\ infratemporal\\ fossa\\ and\\ cavernous\\ sinus\\.\ \(0\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ aggressive\\ neoplasm\\:\ \(0\)\
\-\ 1\\.\\ lymphoma\\,\\ primary\\ cns\\ or\\ metastatic\\ to\\ brain\ \(0\)\
\-\ 2\\.\\ sarcoma\\,\\ primary\\ or\\ metastatic\ \(0\)\
\-\ persistent\\ headache\\ for\\ eight\\ weeks\\ and\\ mental\\ status\\ changes\\.\ \(0\)\
\-\ this\\ case\\ demonstrates\\ cns\\ lymphoma\\'s\\ ability\\ to\\ spread\\ along\\ neural\\ routes\\ and\\ brain\\ surface\\ as\\ well\\ as\\ invade\\ the\\ brain\\ parenchyma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cns\\:\\ 0\\.3679455128977063\ \(0\)\
\-\ brain\\:\\ 0\\.24562383545917052\ \(0\)\
\-\ primary\\:\\ 0\\.24227269934305737\ \(0\)\
\-\ lymphoma\\:\\ 0\\.23465643692662133\ \(0\)\
\-\ fossa\\:\\ 0\\.20620711568341374\ \(0\)\
\-\ sinus\\:\\ 0\\.18980523138545646\ \(0\)\
\-\ routes\\:\\ 0\\.18893860482280742\ \(0\)\
\-\ infratemporal\\:\\ 0\\.1811917340461597\ \(0\)\
\-\ radiation\\:\\ 0\\.17406849397698007\ \(0\)\
\-\ invade\\:\\ 0\\.16693909673688892\ \(0\)\
\-\ as\\:\\ 0\\.15828718321690297\ \(0\)\
\-\ dysarthria\\:\\ 0\\.15820180212397147\ \(0\)\
\-\ therapy\\:\\ 0\\.15092227757077942\ \(0\)\
\-\ eight\\:\\ 0\\.14693053980953977\ \(0\)\
\-\ aphasia\\:\\ 0\\.1461995640070794\ \(0\)\
\-\ metastatic\\:\\ 0\\.14406262144130655\ \(0\)\
\-\ ability\\:\\ 0\\.14224291740017594\ \(0\)\
\-\ maxillary\\:\\ 0\\.1302406792832839\ \(0\)\
\-\ sensitive\\:\\ 0\\.12918596951127934\ \(0\)\
\-\ orbit\\:\\ 0\\.12163630596899219\ \(0\)\
\-\ neural\\:\\ 0\\.12163630596899219\ \(0\)\
\-\ spread\\:\\ 0\\.11798131419754224\ \(0\)\
\-\ mental\\:\\ 0\\.11446237433890502\ \(0\)\
\-\ cavernous\\:\\ 0\\.11392482920984388\ \(0\)\
\-\ aggressive\\:\\ 0\\.1135733139262324\ \(0\)\
\-\ sarcoma\\:\\ 0\\.11017417164864994\ \(0\)\
\-\ surface\\:\\ 0\\.10957997599068861\ \(0\)\
\-\ and\\:\\ 0\\.10855603348365367\ \(0\)\
\-\ cranial\\:\\ 0\\.10734561277692635\ \(0\)\
\-\ parenchyma\\:\\ 0\\.1066896195754399\ \(0\)\
\-\ persistent\\:\\ 0\\.1011926530454222\ \(0\)\
\-\ to\\:\\ 0\\.09850134187358965\ \(0\)\
\-\ tumors\\:\\ 0\\.09659098054025755\ \(0\)\
\-\ very\\:\\ 0\\.09421528692485442\ \(0\)\
\-\ middle\\:\\ 0\\.09391627228249473\ \(0\)\
\-\ typically\\:\\ 0\\.09219941726407396\ \(0\)\
\-\ involving\\:\\ 0\\.09199353985190546\ \(0\)\
\-\ status\\:\\ 0\\.09165444971908078\ \(0\)\
\-\ or\\:\\ 0\\.09137901901120016\ \(0\)\
\-\ headache\\:\\ 0\\.09053752697225831\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0896567276148867\ \(0\)\
\-\ along\\:\\ 0\\.08799019544444878\ \(0\)\
\-\ enhancing\\:\\ 0\\.08227426357968895\ \(0\)\
\-\ changes\\:\\ 0\\.07937409497292655\ \(0\)\
\-\ weeks\\:\\ 0\\.07871233400762377\ \(0\)\
\-\ these\\:\\ 0\\.07416550562865983\ \(0\)\
\-\ case\\:\\ 0\\.0659818558264507\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0659818558264507\ \(0\)\
\-\ well\\:\\ 0\\.0635936134100674\ \(0\)\
\-\ mass\\:\\ 0\\.05016690494484212\ \(0\)\
\-\ are\\:\\ 0\\.049836097474492545\ \(0\)\
\-\ this\\:\\ 0\\.04512946783358352\ \(0\)\
\-\ left\\:\\ 0\\.04480162671909584\ \(0\)\
\-\ for\\:\\ 0\\.0398069804456673\ \(0\)\
\-\ the\\:\\ 0\\.026206321731484097\ \(0\)\
